Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
$18.00
$834.46MN/A11,851 shs39 shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$41.20
-1.3%
$43.75
$19.44
$53.27
$2.99B2.18641,875 shs596,284 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$32.65
-1.9%
$35.66
$6.76
$46.98
$3.20B0.481.98 million shs1.42 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$38.71
+0.3%
$33.83
$26.74
$46.00
$2.98B1.16981,668 shs677,575 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-1.32%-6.58%-6.51%+39.85%-15.09%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-1.89%-8.00%-13.69%+12.08%+261.17%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+0.28%-0.33%+25.80%+34.78%-3.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.0461 of 5 stars
4.61.00.00.03.12.50.0
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
4.509 of 5 stars
4.60.00.04.42.93.30.6
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.2528 of 5 stars
3.51.00.00.03.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00
N/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.11
Buy$58.7642.63% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.20
Buy$45.7540.12% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$53.2037.43% Upside

Current Analyst Ratings Breakdown

Latest CXRXF, SRRK, KYMR, and XENE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$50.00
8/12/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00
8/12/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$57.00 ➝ $55.00
8/12/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$42.00 ➝ $43.00
8/7/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$57.00 ➝ $45.00
7/30/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$60.00
7/30/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetStrong-Buy$53.00
7/17/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
7/15/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00
6/27/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$525.58M1.59N/AN/A$0.16 per share106.63
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$47.07M62.58N/AN/A$13.59 per share3.03
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$33.19M94.57N/AN/A$2.43 per share13.44
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$9.43M316.54N/AN/A$8.22 per share4.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
-$74.86MN/AN/AN/A-15.31%N/A-4.38%N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)

Latest CXRXF, SRRK, KYMR, and XENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million
8/11/2025Q2 2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.03-$1.07-$0.04-$1.07N/AN/A
8/6/2025Q2 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
257.04
2.39
1.61
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.32
8.32
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.21
6.33
6.33
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
15.14
15.14

Institutional Ownership

CompanyInstitutional Ownership
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
13.30%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
4.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
42948.91 millionN/ANot Optionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17071.50 million60.05 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
14096.13 million83.34 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21077.11 million73.97 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVANZ PHARMA stock logo

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)
As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$41.20 -0.55 (-1.32%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$41.78 +0.58 (+1.41%)
As of 08/29/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$32.65 -0.63 (-1.89%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$32.65 0.00 (0.00%)
As of 08/29/2025 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$38.71 +0.11 (+0.28%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$38.70 -0.02 (-0.04%)
As of 08/29/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.